CS-0777 / Daiichi Sankyo - LARVOL DELTA

No differences observed among multiple clinical S1P1 receptor agonists (functional antagonists) in S1P1 receptor down-regulation and degradation (J Biomol Screen) - PMID: 24003058; "Our parallel assessment has allowed us to compare their potency against S1P1, their selectivity against the four other S1P receptors, as well as species cross-reactivity. We note that all of the compounds studied signal in an identical manner through S1P1, leading to receptor degradation."

Preclinical • Multiple Sclerosis

Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients (J Neuroimmunol) - P1, N=25; NCT00616733; CS-0777 resulted in a pronounced, dose-dependent decrease in lymphocytes and CD4 T cell subsets, which returned to baseline within 4weeks after the last dose; CS-0777 was safe and well-tolerated

P1 data • Immunology • Multiple Sclerosis

Daiichi Sankyo: Business Plan - 5 Years (Daiichi Sankyo) - Anticipated approval for multiple sclerosis in FY 2018; Anticipated launch for multiple sclerosis in FY 2018

Anticipated launch non-US • Anticipated non-US regulatory • Multiple Sclerosis

Consolidated financial results for FY2013 (Daiichi Sankyo Press Release) - "Daiichi Sankyo decided to discontinue the development of ASB17061 after reviewing its clinical study result."

Discontinued • Multiple Sclerosis